Metastasis risk assessment using BAG2 expression by cancer-associated fibroblast and tumor cells in patients with breast cancer

Chang Ik Yoon; Sung Gwe Ahn; Yoon Jin Cha; Dooreh Kim; Soong June Bae; Ji Hyung Lee; Akira Ooshima; Kyung Min Yang; Seok Hee Park; Seong Jin Kim; Joon Jeong

doi:10.3390/cancers13184654

Metastasis risk assessment using BAG2 expression by cancer-associated fibroblast and tumor cells in patients with breast cancer

Chang Ik Yoon, Sung Gwe Ahn, Yoon Jin Cha, Dooreh Kim, Soong June Bae, Ji Hyung Lee, Akira Ooshima, Kyung Min Yang, Seok Hee Park, Seong Jin Kim, Joon Jeong

Department of Surgery

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Few studies have examined the role of BAG2 in malignancies. We investigated the prognostic value of BAG2-expression in cancer-associated fibroblasts (CAFs) and tumor cells in predicting metastasis-free survival in patients with breast cancer. Tissue-microarray was constructed using human breast cancer tissues obtained by surgical resection between 1992 and 2015. BAG2 expression was evaluated by immunohistochemistry in CAFs or the tumor cells. BAG2 expression in the CAFs and cytoplasm of tumor cells was classified as positive and negative, and low and high, respectively. BAG2-CAF was evaluated in 310 patients and was positive in 67 (21.6%) patients. Kaplan–Meier plots showed that distant metastasis-free survival (DMFS) was lesser in patients with BAG2(+) CAF than in patients with BAG2(−) CAF (p = 0.039). Additionally, we classified the 310 patients into two groups: 109 in either BAG2-high or BAG2(+) CAF and 201 in BAG2-low and BAG2(−) CAF. DMFS was significantly reduced in patients with either BAG2-high or BAG2(+) CAF than in the patients of the other group (p = 0.005). Multivariable analysis demonstrated that DMFS was prolonged in patients with BAG2(−) CAF or BAG2-low. Evaluation of BAG2 expression on both CAFs and tumor cells could help in determining the risk of metastasis in breast cancer.

Original language	English
Article number	4654
Journal	Cancers
Volume	13
Issue number	18
DOIs	https://doi.org/10.3390/cancers13184654
Publication status	Published - 2021 Sept

Bibliographical note

Funding Information:
Funding: This research was supported by the Basic Science Research Program through the NRF) (NRF-2016R1D1A1A09917675; NRF-2019R1C1C1002830).and grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1520120).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13184654

Cite this

@article{2d09ec785a5b42708bc4ae8a90c01ba9,

title = "Metastasis risk assessment using BAG2 expression by cancer-associated fibroblast and tumor cells in patients with breast cancer",

abstract = "Few studies have examined the role of BAG2 in malignancies. We investigated the prognostic value of BAG2-expression in cancer-associated fibroblasts (CAFs) and tumor cells in predicting metastasis-free survival in patients with breast cancer. Tissue-microarray was constructed using human breast cancer tissues obtained by surgical resection between 1992 and 2015. BAG2 expression was evaluated by immunohistochemistry in CAFs or the tumor cells. BAG2 expression in the CAFs and cytoplasm of tumor cells was classified as positive and negative, and low and high, respectively. BAG2-CAF was evaluated in 310 patients and was positive in 67 (21.6%) patients. Kaplan–Meier plots showed that distant metastasis-free survival (DMFS) was lesser in patients with BAG2(+) CAF than in patients with BAG2(−) CAF (p = 0.039). Additionally, we classified the 310 patients into two groups: 109 in either BAG2-high or BAG2(+) CAF and 201 in BAG2-low and BAG2(−) CAF. DMFS was significantly reduced in patients with either BAG2-high or BAG2(+) CAF than in the patients of the other group (p = 0.005). Multivariable analysis demonstrated that DMFS was prolonged in patients with BAG2(−) CAF or BAG2-low. Evaluation of BAG2 expression on both CAFs and tumor cells could help in determining the risk of metastasis in breast cancer.",

author = "Yoon, {Chang Ik} and Ahn, {Sung Gwe} and Cha, {Yoon Jin} and Dooreh Kim and Bae, {Soong June} and Lee, {Ji Hyung} and Akira Ooshima and Yang, {Kyung Min} and Park, {Seok Hee} and Kim, {Seong Jin} and Joon Jeong",

note = "Funding Information: Funding: This research was supported by the Basic Science Research Program through the NRF) (NRF-2016R1D1A1A09917675; NRF-2019R1C1C1002830).and grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1520120). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = sep,

doi = "10.3390/cancers13184654",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "18",

}

TY - JOUR

T1 - Metastasis risk assessment using BAG2 expression by cancer-associated fibroblast and tumor cells in patients with breast cancer

AU - Yoon, Chang Ik

AU - Ahn, Sung Gwe

AU - Cha, Yoon Jin

AU - Kim, Dooreh

AU - Bae, Soong June

AU - Lee, Ji Hyung

AU - Ooshima, Akira

AU - Yang, Kyung Min

AU - Park, Seok Hee

AU - Kim, Seong Jin

AU - Jeong, Joon

N1 - Funding Information: Funding: This research was supported by the Basic Science Research Program through the NRF) (NRF-2016R1D1A1A09917675; NRF-2019R1C1C1002830).and grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1520120). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/9

Y1 - 2021/9

N2 - Few studies have examined the role of BAG2 in malignancies. We investigated the prognostic value of BAG2-expression in cancer-associated fibroblasts (CAFs) and tumor cells in predicting metastasis-free survival in patients with breast cancer. Tissue-microarray was constructed using human breast cancer tissues obtained by surgical resection between 1992 and 2015. BAG2 expression was evaluated by immunohistochemistry in CAFs or the tumor cells. BAG2 expression in the CAFs and cytoplasm of tumor cells was classified as positive and negative, and low and high, respectively. BAG2-CAF was evaluated in 310 patients and was positive in 67 (21.6%) patients. Kaplan–Meier plots showed that distant metastasis-free survival (DMFS) was lesser in patients with BAG2(+) CAF than in patients with BAG2(−) CAF (p = 0.039). Additionally, we classified the 310 patients into two groups: 109 in either BAG2-high or BAG2(+) CAF and 201 in BAG2-low and BAG2(−) CAF. DMFS was significantly reduced in patients with either BAG2-high or BAG2(+) CAF than in the patients of the other group (p = 0.005). Multivariable analysis demonstrated that DMFS was prolonged in patients with BAG2(−) CAF or BAG2-low. Evaluation of BAG2 expression on both CAFs and tumor cells could help in determining the risk of metastasis in breast cancer.

AB - Few studies have examined the role of BAG2 in malignancies. We investigated the prognostic value of BAG2-expression in cancer-associated fibroblasts (CAFs) and tumor cells in predicting metastasis-free survival in patients with breast cancer. Tissue-microarray was constructed using human breast cancer tissues obtained by surgical resection between 1992 and 2015. BAG2 expression was evaluated by immunohistochemistry in CAFs or the tumor cells. BAG2 expression in the CAFs and cytoplasm of tumor cells was classified as positive and negative, and low and high, respectively. BAG2-CAF was evaluated in 310 patients and was positive in 67 (21.6%) patients. Kaplan–Meier plots showed that distant metastasis-free survival (DMFS) was lesser in patients with BAG2(+) CAF than in patients with BAG2(−) CAF (p = 0.039). Additionally, we classified the 310 patients into two groups: 109 in either BAG2-high or BAG2(+) CAF and 201 in BAG2-low and BAG2(−) CAF. DMFS was significantly reduced in patients with either BAG2-high or BAG2(+) CAF than in the patients of the other group (p = 0.005). Multivariable analysis demonstrated that DMFS was prolonged in patients with BAG2(−) CAF or BAG2-low. Evaluation of BAG2 expression on both CAFs and tumor cells could help in determining the risk of metastasis in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85114950920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114950920&partnerID=8YFLogxK

U2 - 10.3390/cancers13184654

DO - 10.3390/cancers13184654

M3 - Article

AN - SCOPUS:85114950920

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 18

M1 - 4654

ER -

Metastasis risk assessment using BAG2 expression by cancer-associated fibroblast and tumor cells in patients with breast cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this